The Dow Jones shed another 650 points on Tuesday, taking the two-day drop to 1,300 points. The S&P 500 has now given up all the post-Trump election victory gains with another 1.3% drop on Tuesday. The ...

Gabe Whisnant is a Breaking News Editor at Newsweek based in North Carolina. Prior to joining Newsweek in 2023, he directed daily publications in North and South Carolina. As an executive editor ...

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.

NEW YORK, March 4 (Reuters) - Goldman Sachs (GS.N), opens new tab plans to trim its staffing by 3% to 5% in an annual performance review process this spring, said a source familiar with the matter ...

“The state government’s addition of 1300 new homes at Playford Alive East further heightens the need for a long-term solution,” he said. Nearly 20,000 cars a day use Curtis Rd, which runs ...

The plans by the retail giant, in partnership with Coronation Property, include 1300 apartments—a big slice of the 8600 shovel-ready homes given the go-ahead by the authority this time around. Also ...

The National Oceanic and Atmospheric Administration (NOAA) has terminated approximately 1,300 employees in a sweeping reduction that represents about 10 percent of its total workforce, sparking ...

Warrawong is ready for an additional 1,300 well-located homes following the approval of new planning controls for Warrawong Plaza. The planning proposal at 43-65 Cowper Street, Warrawong, increases ...

Mirum Pharmaceuticals’ Ctexli (chenodiol) has gained US Food and Drug Administration (FDA) approval for treating adults with cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease.

Credit: MacroEcon/Shutterstock. Mirum Pharmaceuticals’ Ctexli (chenodiol) has gained US Food and Drug Administration (FDA) approval for treating adults with cerebrotendinous xanthomatosis (CTX), a ...

CTEXLI is the first and only medication approved for the treatment of CTX in adults Approval based on Phase 3 RESTORE study results CTEXLI granted U.S. FDA Orphan Drug exclusivity for the treatment of ...